Adc Therapeutics SA stock has reached a 52-week low, trading at $1.61, as the company faces a challenging market environment. According to InvestingPro analysis, the stock's RSI indicates oversold ...

ADC Therapeutics SA股票在公司面临市场挑战的环境下触及52周新低，交易价格为1.61美元。根据 InvestingPro ...

Tubulis announced today that its second drug candidate, TUB-030, has entered clinical evaluation with successful dosing of ...

attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. About the ADC Portfolio of Daiichi Sankyo The Daiichi Sankyo ADC ...

IPH4502, Innate’s lead ADC, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4, is being investigated in a Phase 1 trial in patients with advanced solid ...

通过对2024年中国创新药十大出海事件的剖析，能为我们提供更多的观察维度。 / 01 / 恒瑞医药60亿美元出海，开创中国药企Newco先河 说到出海，NewCo无疑是热门话题。 所谓NewCo模式，指的是由资本组局成立NewCo，药企将管线剥离给NewCo，获得授权费用及股权。 从 ...